A method of measuring a concentration of an analyte is provided, including: reacting a test solution including an analyte with a nanoparticle solution including a plurality of nanoparticles and an optical waveguide element to form a sandwich-like structure; and measuring evanescent wave energy of the optical waveguide element absorbed and/or scattered by the plurality of nanoparticles after the plurality of nanoparticles forming the sandwich-like structure by using a photodetector to obtain a first signal, and calculating the concentration of the analyte based on the first signal. Wherein, a detection recognition element is conjugated on a surface of each of the plurality of nanoparticles, and a capture recognition element is conjugated on a waveguide surface of the optical waveguide element.

A method for analyzing or detecting methimazole (“MTZ”) comprising contacting a sample suspected of containing MTZ with the dendrimer-stabilized silver nanoparticles and performing surface-enhanced Raman scattering (SERS). Graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag).

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

An electrochemical analyte detection method of cells and biomolecules that does not interfere with optical, genetic, or mass spectrometric detection allows reagents to be added simultaneously. Additional reagents can be included as mass reporters for identification of an analyte and measuring analyte integrity. Analyte integrity and identity allow electronic coupling of electrochemical analyte results to additional optical, genetic, or mass spectrometric results for the analyte. Reagents for mass reporters, electrochemical, and mass spectrometric detection can be added simultaneously to analyte detection microwells with size exclusion filters used for electrochemical signal generation and affinity agents for capturing mass reporters and analytes.

Methods for plasmonic nanoparticle assisted detection of target analytes are provided including methods of plasmonic nanoparticle assisted enzyme-linked immunosorbent assay (ELISA) in a fluidics device. For example, a digital microfluidics (DMF) system is provided that includes a DMF device (or cartridge) in which the methods of plasmonic nanoparticle assisted ELISA may be performed. The disclosed methods for detecting target analytes include measuring an optically detectable change caused by one or a combination of etching, growth, aggregation, or altered interparticle distance of plasmonic particles in the vicinity of a target analyte-capture biomolecule complex in response to a product or byproduct generated by enzyme-substrate reactions. In the methods, the amount of enzyme-substrate reactions is proportional to the number of target analytes bound to the capture biomolecules.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

Provided herein are methods and systems for the production of a nanolipoprotein particle (NLP) that includes a scaffold protein a membrane forming lipid and optionally a target protein. At least one of the scaffold protein and target protein can be provided through an IVT system. The membrane forming lipid, scaffold protein and optionally the target protein can be assembled for a time and under conditions that allow obtaining high yield NLPs, NPLs with an increased solubility, an NLP of a controlled size, and/or an NLP having a size predetermined to include a pre-selected target protein.

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

The disclosure relates to antigen detection reagents and related methods, systems, and kits. The reagents comprise an antigen-binding molecule conjugated to an inorganic component. In some embodiments, the inorganic component possesses catalytic functionality to provide a detectable signal. In some embodiments, the catalytic inorganic component is or comprises a bimetallic nanoparticle. In other embodiments, the inorganic component is a nanoflowers that provides a physical scaffold onto which the antigen-binding component and a reporter component can be loaded, resulting in augmented antigen-binding and reporting capabilities.